{"id":"NCT03448939","sponsor":"Sol-Gel Technologies, Ltd.","briefTitle":"A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea","officialTitle":"A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-18","primaryCompletion":"2019-05-24","completion":"2019-05-24","firstPosted":"2018-02-28","resultsPosted":"2021-12-14","lastUpdate":"2021-12-14"},"enrollment":361,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Papulopustular Rosacea"],"interventions":[{"type":"DRUG","name":"S5G4T-1","otherNames":["Encapsulated benzoyl peroxide (E-BPO) cream"]},{"type":"DRUG","name":"S5G4T-2","otherNames":["Vehicle cream"]}],"arms":[{"label":"S5G4T-1","type":"EXPERIMENTAL"},{"label":"S5G4T-2 Vehicle Cream","type":"PLACEBO_COMPARATOR"}],"summary":"To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.","primaryOutcome":{"measure":"Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12","timeFrame":"Baseline through Week 12","effectByArm":[{"arm":"S5G4T-1","deltaMin":43.5,"sd":null},{"arm":"S5G4T-2 Vehicle Cream","deltaMin":16.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37636253"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":239},"commonTop":["Application site erythema","Nasopharyngitis","Application site pain","Upper respiratory tract infection","Application site pruritus"]}}